NASDAQ:MIRM Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis $101.55 +0.55 (+0.54%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$101.76 +0.22 (+0.21%) As of 09:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Mirum Pharmaceuticals Stock (NASDAQ:MIRM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mirum Pharmaceuticals alerts:Sign Up Key Stats Today's Range$100.01▼$103.3650-Day Range$91.49▼$111.3952-Week Range$47.89▼$114.99Volume868,729 shsAverage Volume669,927 shsMarket Capitalization$6.19 billionP/E RatioN/ADividend YieldN/APrice Target$139.80Consensus RatingModerate Buy Company Overview Mirum Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist. Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage. Maralixibat has achieved regulatory approval in the United States for the treatment of cholestatic pruritus in patients with Alagille syndrome and is under review or in clinical development for other rare cholestatic conditions, including progressive familial intrahepatic cholestasis (PFIC). In addition to its lead compound, Mirum maintains a pipeline of product candidates aimed at expanding the therapeutic options available to patients with orphan liver diseases. Founded in 2016 and headquartered in Brisbane, California, Mirum Pharmaceuticals operates with a patient-centric approach that emphasizes collaboration with advocacy groups and key opinion leaders in hepatology. Under the leadership of President and Chief Executive Officer Derek Chalmers, the company is actively pursuing regulatory approvals and commercial partnerships to bring its therapies to patients in the United States and international markets.AI Generated. May Contain Errors. Read More Mirum Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreMIRM MarketRank™: Mirum Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat, and ranked 116th out of 855 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingMirum Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 1 strong buy rating, 13 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMirum Pharmaceuticals has a consensus price target of $139.80, representing about 37.7% upside from its current price of $101.55.Amount of Analyst CoverageMirum Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Mirum Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($2.01) to $0.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mirum Pharmaceuticals is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mirum Pharmaceuticals is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMirum Pharmaceuticals has a P/B Ratio of 16.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Mirum Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.74% of the float of Mirum Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMirum Pharmaceuticals has a short interest ratio ("days to cover") of 7.92.Change versus previous monthShort interest in Mirum Pharmaceuticals has recently decreased by 19.95%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMirum Pharmaceuticals does not currently pay a dividend.Dividend GrowthMirum Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.5 / 5News Sentiment1.17 News SentimentMirum Pharmaceuticals has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Mirum Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest4 people have searched for MIRM on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows6 people have added Mirum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Mirum Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,344,300.00 in company stock.Percentage Held by Insiders8.32% of the stock of Mirum Pharmaceuticals is held by insiders.Percentage Held by InstitutionsMirum Pharmaceuticals has minimal institutional ownership at this time.Read more about Mirum Pharmaceuticals' insider trading history. Receive MIRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MIRM Stock News HeadlinesMirum and Incyte's zilurgisertib shows positive Phase 2 data in FOPJune 15 at 9:05 AM | seekingalpha.comMirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans ProgressivaJune 14 at 6:58 PM | finance.yahoo.comWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillion in stored capital will be looking for a home when it does. But the real opportunity isn't the IPO itself. Jovine has identified a small-cap supplier trading near $4 that sits directly in the path of xAI's Colossus infrastructure buildout - and a specific trigger in the S-1 could reprice it overnight.June 17 at 1:00 AM | Behind the Markets (Ad)Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Hinge Health, Inc. Class A (HNGE)June 13, 2026 | theglobeandmail.comMirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells $469,100.00 in StockJune 10, 2026 | insidertrades.comMirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL CongressJune 4, 2026 | finance.yahoo.comChristopher Peetz Sells 30,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) StockJune 3, 2026 | insidertrades.comMirum Pharma: A Rare Disease Growth Story to WatchMirum stock pulled back after earnings despite strong growth. Here’s why investors still see upside in the rare disease biotech company...May 20, 2026 | marketbeat.comSee More Headlines MIRM Stock Analysis - Frequently Asked Questions How have MIRM shares performed this year? Mirum Pharmaceuticals' stock was trading at $78.99 at the start of the year. Since then, MIRM shares have increased by 28.6% and is now trading at $101.55. How were Mirum Pharmaceuticals' earnings last quarter? Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced its earnings results on Wednesday, May, 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by $12.68. Mirum Pharmaceuticals's quarterly revenue was up 43.3% on a year-over-year basis. Read the conference call transcript. When did Mirum Pharmaceuticals IPO? Mirum Pharmaceuticals (MIRM) raised $75 million in an initial public offering on Thursday, July 18th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers. Who are Mirum Pharmaceuticals' major shareholders? Mirum Pharmaceuticals' top institutional investors include Janus Henderson Group PLC (11.39%), Rock Springs Capital Management LP (1.33%), Bank of America Corp DE (1.18%) and Bank of New York Mellon Corp (0.96%). Insiders that own company stock include Patrick J Heron, Christopher Peetz, Lara Longpre, Eric Bjerkholt, Peter Radovich, Pamela Vig, Joanne Quan, Laura Brege, Jolanda Howe, Saira Ramasastry and Michael G Grey. View institutional ownership trends. How do I buy shares of Mirum Pharmaceuticals? Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mirum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mirum Pharmaceuticals investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings5/06/2026Today6/17/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 MIRM's financial health is in the Green zone, according to TradeSmith. MIRM has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MIRM CIK1759425 Webmirumpharma.com Phone(650) 667-4085FaxN/AEmployees140Year Founded2018Price Target and Rating Average Price Target for Mirum Pharmaceuticals$139.80 High Price Target$185.00 Low Price Target$77.00 Potential Upside/Downside+37.7%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($13.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$23.36 million Net Margins-140.24% Pretax Margin-140.00% Return on Equity-11.28% Return on Assets-3.84% Debt Debt-to-Equity Ratio1.28 Current Ratio2.09 Quick Ratio1.99 Sales & Book Value Annual Sales$521.31 million Price / Sales11.88 Cash Flow$0.05 per share Price / Cash Flow1,981.20 Book Value$6.12 per share Price / Book16.59Miscellaneous Outstanding Shares60,980,000Free Float55,907,000Market Cap$6.19 billion OptionableOptionable Beta0.50 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:MIRM) was last updated on 6/17/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
